Mach-1 Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Mach-1 Financial Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-293	Closed	-$226K	–	264
2025 Q4	$226K	Buy	+293	New	+$199K	0.05%	255
2024 Q1	–	Sell	-1,216	Closed	-$1.07M	–	185
2023 Q4	$1.07M	Buy	1,216 +631	+108%	+$520K	0.41%	56
2023 Q3	$481K	Buy	+585	New	+$460K	0.2%	131

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mach-1 Financial Group's REGN Position: Q1 2026 in Review

Mach-1 Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 293 shares — an estimated $226K sold.

Mach-1 Financial Group first reported a position in REGN in Q3 2023 and held it in 3 quarters. The position peaked at $1.07M in Q4 2023. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Mach-1 Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Mach-1 Financial Group sold 293 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $226K.
Mach-1 Financial Group first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 3 quarters.
Mach-1 Financial Group's Regeneron Pharmaceuticals position peaked at $1.07M in Q4 2023.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Mach-1 Financial Group's 13F filing for Q1 2026, filed 13 May 2026.